Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yuan Chen

Interventional Pain Medicine North Aurora, IL Medical Doctor

NPI 1811900186 CMS profile 218681

1205 Oak St, North Aurora, IL 60542

Open in the dashboard

General payments

$5,379

254 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yuan Chen of North Aurora, IL is reported in the CMS Open Payments database as having received $5,379 across 254 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $424 19
2024 General $340 16
2023 General $599 29
2022 General $990 41
2021 General $1,212 59
2020 General $621 37
2019 General $1,193 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yuan Chen
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Yuan Chen were reported at $424. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Yuan Chen Interventional Pain Medicine median Middle half National median
2019 $1,193 $684 $216–$2,079 $163
2020 $621 $382 $122–$1,109 $114
2021 $1,212 $552 $167–$1,554 $132
2022 $990 $605 $187–$1,924 $149
2023 $599 $671 $195–$1,915 $160
2024 $340 $684 $206–$1,837 $164
2025 $424 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,223 45 payments
  2. Teva Pharmaceuticals USA, Inc. $726 27 payments
  3. Collegium Pharmaceutical, Inc. $503 33 payments
  4. Pfizer Inc. $472 22 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $239 12 payments
  6. Nevro Corp. $167 7 payments
  7. Horizon Therapeutics plc $158 10 payments
  8. Saol Therapeutics Inc. $144 3 payments
  9. IBSA Pharma Inc. $131 8 payments
  10. Biodelivery Sciences International, Inc. $124 9 payments
  11. Other $1,490 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,379 254 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $739 25 payments
  2. QULIPTA $654 24 payments
  3. Ajovy Central Nervous System $405 11 payments
  4. NURTEC ODT Primary Care $360 19 payments
  5. NURTEC ODT Pain $352 16 payments
  6. AJOVY Central Nervous System $322 16 payments
  7. XTAMPZA $321 18 payments
  8. ZAVZPRET $315 14 payments
  9. LIORESAL (BACLOFEN) $144 3 payments
  10. Licart $131 8 payments
  11. Other $3,112 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

858

Median for Pain Management: 951

Drug cost

$18,702

Median for Pain Management: $26,034

Branded share of claims

48.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 15 $7,599
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 323 $3,852
Celecoxib Generic 44 $3,253
Gabapentin Generic 71 $1,117
Fentanyl Generic 12 $716
Cyclobenzaprine Hcl Generic 68 $390
Methylprednisolone Generic 57 $323
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 47 $321
Acetaminophen-Codeine Acetaminophen With Codeine Brand 34 $304
Tizanidine Hcl Generic 36 $252

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$449,042

Of which drugs: $50,609

Medicare patients

309

Average age 73

Services billed

49,566

180 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Ischemic heart disease 30%
Diabetes 28%
Osteoporosis 23%
Chronic kidney disease 20%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 17 7,155 $35,529
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 19 90 $8,543
Injection, methylprednisolone acetate, 1 mg J1010 Office 196 38,029 $3,909
Injection, methylprednisolone acetate, 80 mg J1040 Office 101 160 $1,208
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 50 57 $16
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 86 118 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $46
$46 — —
ZAVZPRET
  • PFIZER INC. $46
$46 — —
BOTOX
  • AbbVie, Inc. $42
$42 — 7,155
UBRELVY
  • AbbVie, Inc. $35
$35 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

254 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record